Literature DB >> 28616312

PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies.

Minghui Zhang1, Di Feng2, Jing Jing1, Hang Liu1, Shu Zhao1, Qingyuan Zhang1.   

Abstract

Entities:  

Year:  2017        PMID： 28616312      PMCID： PMC5465173          DOI： 10.21037/jtd.2017.04.34

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  13 in total

1.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.

Authors:  Marianne J Ratcliffe; Alan Sharpe; Anita Midha; Craig Barker; Marietta Scott; Paul Scorer; Hytham Al-Masri; Marlon C Rebelatto; Jill Walker
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

2.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

Review 3.  PD-1 and PD-L1 antibodies in cancer: current status and future directions.

Authors:  Arjun Vasant Balar; Jeffrey S Weber
Journal:  Cancer Immunol Immunother       Date:  2017-02-17       Impact factor: 6.968

4.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

Review 6.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

9.  The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.

Authors:  Minghui Zhang; Yuandi Dong; Haitao Liu; Yan Wang; Shu Zhao; Qijia Xuan; Yan Wang; Qingyuan Zhang
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

Review 10.  PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.

Authors:  Jun Wang; Ruirong Yuan; Wenru Song; Jingwei Sun; Delong Liu; Zihai Li
Journal:  J Hematol Oncol       Date:  2017-01-25       Impact factor: 17.388
View more
  2 in total

1.  Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.

Authors:  Jianli Ma; Decai Chi; Yan Wang; Yubo Yan; Shu Zhao; Hang Liu; Jing Jing; Haihong Pu; Minghui Zhang
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

2.  PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.

Authors:  Trine Vilsbøll Larsen; Dianna Hussmann; Anders Lade Nielsen
Journal:  Cancer Commun (Lond)       Date:  2019-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.